U.S. House Oversight Committee to subpoena AbbVie in drug-pricing probe
Reuters
Published Sep 01, 2020 10:33AM ET
Updated Sep 01, 2020 11:10AM ET
(Reuters) - The U.S. House Oversight Committee on Tuesday decided to subpoena AbbVie Inc (N:ABBV) to seek documents on the drugmaker's blockbuster treatments, Humira and Imbruvica, as part of its investigation into drug pricing practices.
The committee began probing into pharmaceutical industry pricing practices last year and had sought information from 12 drugmakers on price increases, corporate strategies to preserve market share and pricing power.
"After more than 18 months, AbbVie has demonstrated its unwillingness to comply voluntarily with the Committee's investigation," Representative Carolyn Maloney, the Chairwoman of the committee, wrote in a memo https://oversight.house.gov/sites/democrats.oversight.house.gov/files/documents/2020-09-01%20AbbVie%20Subpoena%20Memo.pdf.
"Although most of the drug companies we are examining have cooperated with the committee's investigation, AbbVie's noncompliance stands out as particularly egregious, which is why I am issuing this subpoena."
AbbVie did not immediately respond to Reuters request for comment.
Shares of the drugmaker fell nearly 3% to $93.10 on Tuesday.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.